Progen Co., Ltd. (XKON: 296160)
7,090.00
0.00 (0.00%)
At close: Sep 10, 2024
Progen Company Description
Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities.
The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments.
It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes.
The company was founded in 1998 and is based in Seoul, South Korea.
Progen Co., Ltd.
Country | South Korea |
Founded | 1998 |
Industry | Biological Products, Except Diagnostic Substances |
Contact Details
Address: 7th floor, Bio Innovation Park Seoul, 07630 South Korea | |
Phone | 82 2 6098 2800 |
Website | progen.co.kr |
Stock Details
Ticker Symbol | 296160 |
Exchange | Korea New Exchange |
Reporting Currency | KRW |
SIC Code | 2836 |